Cellular Dynamics: Human Cells. Endless Possibilities from Discovery to Regenerative Medicine.
CDI Notebook
TrendingArticlesCDI in the NewsUpcoming EventsApplications
CDI Notebook
Welcome to CDI Notebook
Trending: CDI's Knowledge Base

Move to the Front of the Queue! And keep your iCell fueled initiatives on target by consulting our Knowledge Base. This searchable FAQ library provides expert advice in the areas of plating and media, cell culture, general assay methods, and more.

Knowledge Base >>

Article: The Antineoplastic Drug, Trastuzumab, Dysregulates Metabolism in iPSC-derived Cardiomyocytes

The Antineoplastic Drug, Trastuzumab, Dysregulates Metabolism in iPSC-derived Cardiomyocytes. Discover how researchers at the Mayo Clinic are using iCell Cardiomyocytes to investigate cardio-oncology. Their findings identified potential early biomarkers of trastuzumab-induced cardiotoxicity.

Necela B, Axenfeld B, et al. (2017) Clin Transl Med.


Article: iPSC-derived Human Microglia-like Cells to Study Neurological Diseases

iPSC-derived Human Microglia-like Cells to Study Neurological Diseases. Explore the generation of human iPSC-derived microglia-like cells (iMGLs) and the whole-transcriptome and functional analyses implemented to confirm microglial identity. iMGLs can be used to study the biological processes of neurological diseases, such as Alzheimer's Disease gene function.

Abud EM, Ramirez RN, et al. (2017) Neuron.


CDI in the News
CDI in the News: CDI and Harvard University Stem Cell Institute Collaboration

CDI Adds to Stem Cell Work with Harvard Stem Cell Institute. Learn about the Harvard Stem Cell Institute and CDI collaboration to facilitate access to human iPSC-derived cells by the institute's network and the Boston area research community.


CDI in the News: CDI and STEMCELL Technologies Distribution Deal

CDI Signs Distribution Deal with STEMCELL Technologies. Read how STEMCELL Technologies and CDI are teaming to further healthcare innovation by making iPSC-differentiated cell types available to researchers worldwide.


Upcoming Events
Upcoming Event: APT

APT (May 15 - 17 | South San Francisco, CA). Check out the latest on toxicity testing with iCell and MyCell products by attending the following:

 Human iPSC-derived Cardiomyocytes, Glutamatergic Neurons, and Hepatocytes; Cells and Solutions to Improve Toxicity Testing Relevance and Predictivity (May 16 | 1:30 - 2 pm | Podium Talk)

 Evaluating Networked Activity as an Integrated Assay for Seizurogenic Assessment Using Stem Cell-derived Glutamatergic Neurons (Poster)

 3D and 2D in Vitro Models of Xenobiotic-induced Hepatotoxicity using iCell Hepatocytes 2.0 (Poster)

 Advances in Human Induced Pluripotent Stem Cell Derived Cardiomyocytes: Maintaining Validated Responses and Enabling Relevant Toxicity Testing (Poster)

CDI @ APT >>

Upcoming Event: ISSCR

ISSCR (Jun 14 - 17 | Boston, MA | Booth 707). Join us to discuss tools and techniques transforming stem cell science studies including:

 Human iPSC-derived Midbrain Dopaminergic Neurons for Disease Modeling and Cell Therapy (Jun 15 | 11:30 am - 12:30 pm | Innovation Showcase)

 Phenotypic Analysis of Human iPSC-derived Dopaminergic Neurons Harboring the Alpha-synuclein A53T Mutation (Poster)

 Functional Assays to Access Neurotoxicity with Human iPSC-derived Neurons (Poster)

 Cell Line Resources from Parkinson’s Progression Markers Initiative (PPMI) Participants (Poster)

 GMP-compatible iPSC Derivation from Multiple Perinatal Tissue Sources from the Same Donors (Poster)


Application: iCell GlutaNeurons - Measuring Neuronal Activity

iCell GlutaNeurons Application Protocol: Measuring Neuronal Activity. Follow stepwise instructions on culturing iCell GlutaNeurons directly on a Maestro multielectrode array system (Axion Biosystems) to form neuronal networks amenable to electrophysiological interrogation. This protocol also provides guidance for analyzing acquired data.


Follow UsCDI TwitterCDI LinkedInCDI FacebookCDI Youtube

© 2017 FUJIFILM Cellular Dynamics Inc., 525 Science Drive, Madison, WI 53711
+1 (608) 310-5100 or toll-free (877) 310-6688